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ABSTRACT 19 
Transmembrane protein 168 (TMEM168) comprises 697 amino acid residues, including some 20 
putative transmembrane domains. It is reported that TMEM168 controls methamphetamine (METH) 21 
dependence in the nucleus accumbens (NAc) of mice. Moreover, a strong link between METH 22 
dependence-induced adaptive changes in the brain and mood disorders has been evaluated. In the 23 
present study, we investigated the effects of accumbal TMEM168 in a battery of behavioral 24 
paradigms. The adeno-associated virus (AAV) Tmem168 vector was injected into the NAc of 25 
C57BL/6J mice (NAc-TMEM mice). Subsequently, the accumbal TMEM168 mRNA was increased 26 
approximately by seven-fold when compared with the NAc-Mock mice (controls). The NAc-TMEM 27 
mice reported no change in the locomotor activity, cognitive ability, social interaction, and 28 
depression-like behaviors; however, TMEM168 overexpression enhanced anxiety in the 29 
elevated-plus maze and light/dark box test. The increased anxiety was reversed by pretreatment with 30 
the antianxiety drug diazepam (0.3 mg/kg i.p.). Moreover, the NAc-TMEM mice exhibited decreased 31 
prepulse inhibition (PPI) in the startle response test, and the induced schizophrenia-like behavior was 32 
reversed by pretreatment with the antipsychotic drug risperidone (0.01 mg/kg i.p.). Furthermore, 33 
accumbal TMEM168 overexpression decreased the basal levels of extracellular GABA in the NAc 34 
and the high K⁺  (100 mM)-stimulated GABA elevation; however, the total contents of GABA in the 35 
NAc remained unaffected. These results suggest that the TMEM168-regulated GABAergic neuronal 36 
system in the NAc might become a novel target while studying the etiology of anxiety and 37 
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sensorimotor gating deficits. 38 
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INTRODUCTION 39 
Accumulating evidence indicates a link between the mood disorders and drug addiction within the 40 
brain’s rewarding circuitry [1, 2]. Mice chronically administered with methamphetamine (METH), 41 
are generally used as a model to learn about the psychiatric disorders. The model is described by 42 
related behavioral alterations, which suggests long-lasting influences on the gene and protein 43 
expression within specific brain subregions, including the nucleus accumbens (NAc), striatum, 44 
prefrontal cortex, and hippocampus [3-5]. Recently, several studies have attempted to elucidate the 45 
link between the METH-induced maladaptive molecular changes in the brain and behavioral 46 
alterations [4, 6, 7]. These studies may be crucial in discovering the mechanisms involved in the 47 
regulation of psychiatric phenomena and may also suggest novel targets for pharmacotherapy. 48 
Considering using animal models of addiction to study mood disorders, we focused on the NAc, 49 
which plays an important role in both reward circuitry and mood regulation [1, 2]. Several 50 
psychostimulant adaptive molecules in the NAc are known to be involved in psychiatric disorders, 51 
including the cAMP response element-binding protein (CREB) [8, 9], brain-derived neurotrophic 52 
factor (BDNF) [10, 11], orexin [12], and Shati/Nat8l [5, 13]; however, key signaling pathways and 53 
novel molecular cascades related to behavioral regulation still remain to be identified. In a recent 54 
study, we administered METH (2 mg/kg) in mice for 6 days, and then performed a polymerase 55 
chain reaction-selected cDNA subtraction in the NAc of mice [3]. We found that a novel molecule 56 
transmembrane protein 168 (TMEM168; GenBank accession number NM_028990) was increased 57 
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in the brain, especially in the NAc and hippocampus [14]. The accumbal overexpressed TMEM168 58 
plays a crucial role in controlling the METH-induced pharmacological actions [14]; however, 59 
whether TMEM168 in the NAc is associated to the other behavioral changes in vivo still needs to 60 
be evaluated.  61 
In the present study, the adeno-associated virus (AAV) comprising tmem168 cDNA was 62 
microinjected into the NAc of mice to overexpress TMEM168 mRNA. A series of behavioral tests 63 
were performed to explore the behavioral changes following the interruption of the injections of 64 
TMEM168. Furthermore, the in vivo microdialysis analysis was conducted to elucidate the 65 
functional role of TMEM168 in the NAc. We identified TMEM168 in the NAc as a novel target to 66 
induce anxiety and schizophrenia-like symptoms, by inhibiting the GABAergic system in the NAc. 67 
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MATERIALS AND METHODS 68 
 69 
Animals  70 
Male C57BL/6J mice (8-week old; Nihon SLC, Inc. Hamamatsu, Japan) were housed in plastic cages 71 
with a 12 h light/dark cycle (8 am–8 pm). The health and welfare of the animals was 72 
monitored by staff at least once a day. All procedures were in accordance with the National 73 
Institute of Health Guideline for the Care and Use of Laboratory Animals and were approved by the 74 
Animal Experiments Committee of the University of Toyama (Permit Number A2015pha-21). 75 
 76 
Drugs  77 
Diazepam (045-18901; Wako Pure Chemical Industries, Japan) was dissolved in saline and 1% 78 
Tween80. Risperidone (R3030; Sigma-Aldrich, Japan) was dissolved in saline. The behavioral 79 
experiments were performed 30 min after the drug administration. The mice administered with 80 
diazepam or risperidone were not used for other behavioral experiments. 81 
 82 
AAV microinjection 83 
The AAV vector was produced according to previously described methods [15] by encoding cDNA 84 
tmem168 (GenBank accession number NM_028990). Mice were anesthetized with a combination 85 
anesthetic (medetomidine (0.3 mg/kg), midazolam (4.0 mg/kg), and butorphanol (5.0 mg/kg)), and 86 
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were fixed in a stereotactic frame (SR-5M, Narishige, Tokyo, Japan). AAV-TMEM168 vector or 87 
AAV-Mock vector (0.7 μl/side) was injected bilaterally into the NAc (1.5 mm anterior and 0.8 mm 88 
lateral from bregma, 3.9 mm below the skull surface [16]; NAc-TMEM mice or NAc-Mock mice at a 89 
speed of 0.05 µL/min. Mice were used for the experiments 3 weeks later. 90 
All procedures were in accordance with the Guideline for Recombinant DNA Experiment from the 91 
Ministry of Education Culture, Sports, Science, and Technology, Japan and were approved by the 92 
Gene Recombination Experiment Safety Committee of the University of Toyama (Permit Number 93 
G2015pha-21). 94 
 95 
Quantitative real time RT-PCR analysis 96 
After 3 weeks of AAV microinjection, the NAc-Mock mice and NAc-TMEM mice were decapitated 97 
by animal guillotine without feeling any suffering and the brains were quickly removed, since the 98 
fresh brain tissues were needed for the isolation of mRNA or brain slices. This procedure 99 
were done without anesthesia to avoid the effect of anesthetic drugs. All procedures 100 
followed the National Institute of Health Guideline for the Care and Use of Laboratory 101 
Animals (NIH publication No. 85–23, revised in 1996) and were approved by the 102 
committee for Animal Experiments of the University of Toyama (Permit Number 103 
A2015-PHA21). The NAc tissues were dissected according to the atlas of mouse brain [16] and 104 
were preserved at −80 °C until further use. The analysis of real time RT-PCR was described as a 105 
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previous method [14]. The total RNA (1 μg) from each tissue was extracted (RNeasy Plus Mini Kit 106 
protocol; QIAGEN, Tokyo, Japan) and was converted into cDNA using the Prime Script RT reagent 107 
kit (Takara, Shiga, Japan), following the manufacturer’s instructions. Quantitative real time RT-PCR 108 
was performed in a Thermal Cycler Dice Real Time System (Takara) using Power SYBR Green PCR 109 
Master Mix (Applied Biosystems, Foster, CA) with cDNA and primers (1 µM), according to the 110 
manufacturer’s recommendation. The primers of TMEM168 used for real time RT-PCR were as 111 
follows: 5'-GACAGAATCATGGCATCCAAAGG-3', and 112 
5'-ATGGACTCCAGCGGCAAGACAA-3'. The 36B4 transcript amount was quantified using 113 
primers 5'-ACCCTGAAGTGCTCGACATC-3', and 5'-AGGAAGGCCTTGACCTTTTC-3'. 114 
 115 
Schedule of the behavioral tests 116 
We performed the behavioral tests in the following order: locomotor activity test, Y-maze test, novel 117 
object recognition test, social interaction test, elevated plus maze test, light/dark box test, tail 118 
suspension test, forced swim test, and prepulse inhibition test. The time interval between each test 119 
was 2–3 days. 120 
 121 
Fu et al. 
9 
 
Locomotor activity test 122 
The locomotor activity test was performed, as previously reported [17]. Mice were placed into a 123 
Plexiglas box with a frosting Plexiglas floor (40 × 40 × 30 cm), and the test was performed for 60 124 
min using digital counters with infrared sensors (Scanet MV-40; MELQEST, Toyama, Japan). 125 
 126 
Y-maze test 127 
Y-maze test was performed, according to a previously described method [18]. The three-arm maze 128 
(each arm measuring 40 cm × 3 cm × 12 cm) was used for the test. Mice were placed at the end of 129 
one arm and were allowed to move freely through the maze for 10 min. During this time, the arm 130 
entries were enumerated. Alternation was defined as successive entries into the three arms on the 131 
overlapping triplet sets. The percentage alternation was calculated using the following formula: 132 
(number of alternations)/(total number of arm entries-2) × 100. 133 
 134 
Novel object recognition test 135 
Novel object recognition test was performed, according to a previously described method [18]. After 136 
habituation for 3 days, the NAc-Mock or NAc-TMEM mice were allowed to explore two familiar 137 
floor-fixed objects (A and B) in a Plexiglas box (30 cm × 30 cm × 35 cm) for 10 min (familiar 138 
process). The familiar object A and a novel object C were set in the Plexiglas box 24 h after the trail 139 
and the mice were allowed to explore the novel object process for 10 min (novel process). The 140 
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exploratory preference percentage was calculated using the following formula: (approach time of 141 
object B or C)/(total approach time of the two objects in each process) × 100. 142 
 143 
Social interaction test 144 
Social interaction test was performed according to a previously described method [19]. The 145 
apparatus for this test was designed as a Plexiglas box (60 cm × 40 cm × 22 cm) comprising three 146 
connected chambers. After habituation for 2 days, both the NAc-Mock and NAc-TMEM mice were 147 
randomly assigned to a partner male mouse, which was confined to one side of the chamber. The test 148 
mice were placed in the apparatus for 10 min and the total duration they spent interacting with the 149 
partner mouse was recorded. 150 
 151 
Elevated plus-maze test 152 
Elevated plus-maze test was performed according to a previously described method [20]. The 153 
apparatus comprised four black plastic arms (25 cm × 5 cm). Two opposite arms were enclosed by 154 
walls (15 cm in height) and the other two “open” arms had only a small rim (0.2 cm) around the 155 
edges. The apparatus was elevated to a height of 70 cm above the floor level. For testing, mice were 156 
placed in the center region facing an open arm, and were allowed to freely explore the maze for 10 157 
min. The time spent on open arms and the number of entries into the open arms was evaluated. 158 
 159 
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Light–dark box test 160 
Light–dark test was performed according to a previously described method [20]. The apparatus 161 
comprised two plastic chambers. The dark chamber (black plastic) measured 15 cm × 15 cm × 20 cm 162 
(l × w × h) and was covered by a lid. The light chamber, 15 cm × 15 cm × 20 cm (l × w × h), made of 163 
transparent plastic, was brightly illuminated from above with tubular fluorescent lamps (1000 lux). 164 
Mice were placed into the dark chamber and their behaviors were monitored by Scanet MV-40 LD 165 
(MELQUEST) for 10 min. The time spent in the light box was measured. 166 
 167 
Tail suspension test 168 
Tail suspension test was performed according to a previously described method [19]. The mice were 169 
suspended by their tails, i.e., the body dangled in the air, with the head pointing downward. The 170 
duration of immobility from 2 min to 6 min within the 10 min test was recorded visually. 171 
 172 
Forced swim test 173 
Forced swim test was performed according to a previously described method [19]. Mice were placed 174 
in a transparent Plexiglas cylinder (diameter: 14.5 cm; height: 19 cm), ﬁlled with water (depth: 15 175 
cm; temperature: 25 °C). The immobility time was monitored by Scanet MV-40 AQ (MELQUEST) 176 
from 2 min to 6 min within the 10 min test. 177 
 178 
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Prepulse inhibition test 179 
Prepulse inhibition (PPI) test was performed according to a previously described method [21]. The 180 
test was evaluated using the SR-LAB apparatus (San Diego Instruments, CA, USA). Briefly, the test 181 
was performed by exposing the animals to a 70 dB background noise. After a 5 min acclimatization 182 
period, 5 pulses (120 dB each lasting 40 ms) were presented. Subsequently, the randomly prepulse 183 
plus pulse trials were administered as a 20 ms prepulse of 74, 78, 82 or 86 dB, followed by a 100 ms 184 
delay and a startle pulse (120 dB each lasting 40 ms). Eventually, 5 pulses (120 dB each lasting 40 185 
ms) were presented once again. The PPI was calculated as (1 − [startle amplitude on prepulse + pulse 186 
trial/mean startle amplitude on pulse alone trials]) × 100. 187 
 188 
Tissue extraction 189 
From each brain, the NAc tissue was bilaterally extracted and homogenized in a homogenizing 190 
buffer, containing 200 mM perchloric acid and 100 μM ethylenediaminetetraacetic acid (EDTA). The 191 
homogenates were kept in ice for 30 min and were then centrifuged at 20,000 × g for 15 min at 0 °C. 192 
Supernatant was collected and was adjusted to pH 3.0 by adding 1 M sodium acetate. After filtration 193 
(0.45 μm Membrane Filter, MF-Millipore, Japan), the extraction samples was preserved at −80 °C 194 
until the measurement by high-performance liquid chromatography (HPLC). 195 
 196 
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In vivo microdialysis 197 
In vivo microdialysis was performed according to a previously described method [17]. The guide 198 
cannula (AG-4, Eicom, Kyoto, Japan) was implanted into the NAc (+1.5 mm anterolateral, +0.7 mm 199 
mediolateral from bregma, and +3.25 mm dorsoventral from dura mater). On the following day, a 200 
dialysis probe (A-I-4-01, Eicom) was inserted into the guide cannula, and a ringer’s solution (147 201 
mM NaCl, 4 mM KCl, and 2.3 mM CaCl2) was continuously perfused through the probe into the left 202 
side of the NAc. 203 
In the case of GABA dialysis, the dialysate was collected every 30 min at a rate of 1.0 μL/min by a 204 
fraction collector (EF-80; Eicom), placed in biotubes and preserved at −80 °C until it was subjected 205 
to HPLC. High K⁺-stimulation (100 mM) was applied for 15 min, 4.5 h after the probe insertion. The 206 
baseline of extracellular GABA levels was the mean of the averages amount of the last three samples 207 
before high K⁺-stimulation. The 100 mM K+ solution means an identical amount of sodium is 208 
replaced in the ringer’s solution with potassium. 209 
In case of dopamine and serotonin dialysis, the dialysate was collected in 15 min fractions at a rate of 210 
0.5 μL/min and was simultaneously subjected to HPLC.  211 
 212 
HPLC Detection 213 
Using sampling injector (M-500; Eicom), 7 μL of o-phthalaldehyde solution (4 mmol/L) and 0.04% 214 
mercaptoethanol in carbonate buffer (pH 9.5) were added to a 21 μL of dialysate sample or extraction 215 
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sample. Subsequently, 21 μL of the mixture was injected into the HPLC system (HTEC-50; Eicom). 216 
GABA was separated on the SA-50DS column (Eicom), which was maintained at 25 °C, using a 217 
phosphate buffer (pH 3.5) containing EDTA (0.5 μg/L) and 50% methanol as the mobile phase with a 218 
flow rate of 500 μL/min. An electrochemical detector that used a glassy carbon and a working 219 
electrode (set at +600 mV) against a silver–silver chloride reference electrode (WE-GC; Eicom) was 220 
used to quantify the compounds. Chromatograms were controlled by an integrator (PowerChrom: 221 
AD Instruments, NSW, Australia) connected to a personal computer. 222 
In the case of dopamine and serotonin detection, the dialysate was injected into the HPLC system 223 
(HTEC-50; Eicom) directly by an auto injector (Eicom). Dopamine and serotonin were separated on 224 
a PP-ODS column (Eicom), which was maintained at 25 °C, using a phosphate buffer (pH 6.0) 225 
containing decane sulfonic acid (0.5 g/L), EDTA (50 μg/L), and 1% methanol as the mobile phase at 226 
a flow rate of 500 μL/min. An electrochemical detector that used a glassy carbon working electrode 227 
(set at + 400 mV) against a silver–silver chloride reference electrode (WE-3G; Eicom) was used to 228 
quantify the compounds. Four hours after the probe was inserted, the baseline of dopamine and 229 
serotonin levels was measured as the average of the last three samples. Chromatograms were 230 
controlled by an integrator (PowerChrom: AD Instruments, NSW, Australia) connected to a personal 231 
computer. 232 
 233 
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Statistical Analyses 234 
All data were expressed as the mean ± standard error of mean (S.E.M.). Statistical differences 235 
between the two groups were determined using a Student’s t-test. Statistical differences among 236 
values for individual groups were determined by one-way analysis of variance (ANOVA), followed 237 
by the Bonferroni’s post hoc tests when F ratios were significant (p < 0.05). The influences of drug 238 
administration on individual groups were determined by two-way ANOVA, followed by the 239 
Bonferroni’s post hoc tests when F ratios were significant (p < 0.05). To analyze the GABA 240 
development in the microdialysis experiment, statistical differences were evaluated by ANOVA with 241 
repeated measurement, followed by Bonferroni’s post hoc tests (Prism version 5). 242 
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RESULTS 243 
 244 
Microinjection of AAV-TMEM168 vector increased the TMEM168 245 
mRNA expression in the NAc 246 
The mRNA expression level was measured by using real time RT-PCR experiment and was presented 247 
as the value relative to 36B4 mRNA level. The average of the TMEM168 mRNA levels in the 248 
NAc-TMEM mice was 0.214 ± 0.05 and the average of TMEM168 mRNA levels in the NAc-Mock 249 
mice (controls) was 0.0282 ± 0.003. TMEM168 mRNA levels in the NAc of the NAc-TMEM mice 250 
were increased significantly when compared with the levels in the NAc-Mock mice (N = 6, p < 0.01, t 251 
= 3.979; Student-t test). 252 
 253 
Overexpression of TMEM168 did not change the locomotion, 254 
spontaneous alternation, cognitive ability, social interaction, and 255 
depression-like behaviors in mice  256 
A series of behavioral tests were performed to detect the changes in the emotional behavior induced by 257 
TMEM168 overexpression. The NAc-TMEM mice reported no changes in the locomotor activity test 258 
(Fig 1A, t = 1.167) or the Y-maze test (Fig 1B, t = 0.9495), novel object recognition test (Fig 1C, F(3, 259 
32) = 20.98), three chamber social interaction test (Fig 1D, F(3, 32) = 15.7), tail suspension test (Fig 1E, t 260 
= 0.2432), and forced swimming test (Fig 1F, t = 0.7084) when compared with the NAc-Mock mice.  261 
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 262 
Figure 1 Similar preferences in locomotor activity, Y-maze, novel object recognition, three 263 
chambers, tail suspension, and forced swimming tasks in the NAc-TMEM mice compared with 264 
the NAc-Mock mice (A) The locomotor activity in the NAc-Mock and NAc-TMEM mice were 265 
measured for 60 min (No significant difference; Student-t test). (B) Working memory was assessed in 266 
the Y-maze spontaneous alternation task in the NAc-Mock and NAc-TMEM mice (No significant 267 
difference; Student-t test). (C) Cognitive function was assessed in the novel object recognition task. 268 
Percentage of total exploratory time on the novel object was expressed as exploratory preference (%) 269 
(No significant difference; ANOVA followed by the Bonferroni’s post hoc tests). (D) Social interaction 270 
was assessed in the three chambers task. Average time (10 min per phase) spent in the chamber with 271 
an object or a stranger mouse was detected (No significant difference; ANOVA followed by the 272 
Bonferroni’s post hoc tests). (E) Immobility time of the NAc–-Mock and NAc-TMEM mice in the 273 
tail-suspension task was measured for 5 min (No significant difference; Student-t test). (F) Immobility 274 
time of the NAc-Mock and NAc-TMEM mice in the forced swimming task was measured for 5 min 275 
(No significant difference; Student-t test). Values are presented as mean ± S.E.M. N = 9. 276 
 277 
Overexpression of TMEM168 in the NAc induced the increased 278 
anxiety and decreased sensorimotor gating in mice 279 
TMEM168 overexpression in the NAc increased anxiety in mice, such as entries (Fig 2A, p < 0.05, t = 280 
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2.844) and time (Fig 2B, p < 0.05, t = 2.2.253) on open arms in the elevated plus-maze) as well as 281 
time in the light box in light/dark box tasks (Fig 2C, p < 0.05, t = 2.964). Although the startle 282 
responses were not affected (Fig. 2D, F(11, 96) = 58.07), decreased sensorimotor gating in the 283 
NAc-TMEM mice was observed in the prepulse intensity of 74 dB and 82 dB in the auditory PPI test 284 
(Fig. 2E, p < 0.05, F(7, 64) = 16.61). It is suggested that overexpression of TMEM168 in the NAc 285 
induced sensorimotor gating deficit in mice. 286 
 287 
Figure 2 Increased anxiety and decreased PPI in the NAc-TMEM mice compared with the 288 
NAc-Mock mice (A) Number of entries spent on open arms were measured for 10 min in the elevated 289 
plus-maze task; N = 9; Values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-Mock (Student-t 290 
test). (B) Time spent on open arms was measured for 10 min in the elevated plus-maze task; N = 9; 291 
Values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-Mock (Student-t test). (C) Time in the light 292 
box was measured for 10 min in the light/dark box task; N = 9; Values are presented as mean ± S.E.M. 293 
*p < 0.05 vs. NAc-Mock (Student-t test). (D) Startle responses were measured at 70, 80, 90, 100, 110, 294 
and 120 dB, respectively (background noise: 70 dB). N = 9; Values are presented as mean ± S.E.M. No 295 
significant difference between NAc-TMEM and NAc-Mock mice (ANOVA followed by the 296 
Bonferroni’s post hoc tests). (E) PPI was measured for 74, 78, 82, and 86 dB, respectively, of the 297 
prepulse intensity (background noise: 70 dB). Values are presented as mean ± S.E.M. N = 9. *p < 0.05 298 
vs NAc-Mock (ANOVA followed by the Bonferroni’s post hoc tests).  299 
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 300 
Anxiety-like behaviors induced by TMEM168 overexpression in 301 
the NAc were reversed by the administration of diazepam 302 
Diazepam is an (Food and Drug Administration in USA (FDA)-approved benzodiazepine known to 303 
alleviate anxiety, by activating the inotropic GABAA receptors [22]. To investigate whether the 304 
anxiety-like behaviors detected in the NAc-TMEM mice could be reduced by the administration of 305 
anxiolitic drugs, mice were administered with diazepam (0.3 mg/kg i.p.) or vehicle, 30 min before a 306 
performance in the elevated plus-maze and the light/dark box tasks. The dose of diazepam for mice 307 
administration was referred to the previous study [23], which would not affect anxious behaviors in 308 
mice as a criticality. In the elevated plus-maze tasks, the decreased number of open arm entries in the 309 
TMEM mice was reversed (Fig 3A, F(1, 20) = 1.169, p < 0.05) and the decreased time spent in open 310 
arms tend to be normalized in the NAc-TMEM mice (Fig 3B, F(1, 20) = 5.2), following the 311 
administration of diazepam. Similarly, in the light/dark box task, the decreased time spent in the light 312 
box in the NAc-TMEM mice was also reversed after the administration of diazepam (Fig 3C, F(1, 28) = 313 
1.628, p < 0.05). 314 
 315 
Fig 3. Reversal of anxiety behaviors in the elevated plus-maze and light/dark box task following 316 
the administration of diazepam in the NAc-TMEM mice (A) and (B) Diazepam (0.3 mg/kg i.p.) or 317 
vehicle was administered 30 min before performance in the elevated plus-maze task. Number of 318 
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entries and time on open arms were measured for 10 min in the elevated plus-maze task, N = 6; Values 319 
are presented as mean ± S.E.M. *p < 0.05 vs. NAc-TMEM (VEH) (two-way ANOVA followed by the 320 
Bonferroni’s post hoc tests). (C) Diazepam (0.3 mg/kg i.p.) or vehicle was administered 30 min before 321 
the light/dark box test. Time in the light box was measured for 10 min in the light/dark box test, N = 8; 322 
values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-TMEM (VEH) (two-way ANOVA followed 323 
by the Bonferroni’s post hoc tests); VEH: vehicle administration group, DZP: diazepam administration 324 
group. 325 
 326 
Decreased PPI induced by TMEM168 overexpression in the NAc 327 
was reversed following the administration of risperidone 328 
Sensorimotor gating deficit, which is detected by auditory PPI test, is assumed to be a distinctive 329 
phenomenon of schizophrenia [24]. Previous studies reported that antipsychotic drugs, such as 330 
risperidone, significantly reverse the low levels of sensorimotor gating [25]. Mice were injected with 331 
risperidone (0.1 mg/kg i.p.) or saline, 30 min before performing the auditory PPI task. The 332 
concentration of risperidone administration was referred to the previous studies [26, 27], which would 333 
not affect locomotor activity and startle response in mice. No between-group difference was observed 334 
in the startle response to any pulse intensity between the NAc-Mock mice and NAc-TMEM mice, 335 
when these were administrated with saline or risperidone (Fig 4A, F(11, 162) = 0.6238). However, the 336 
decreased PPI in the NAc-TMEM mice was reversed following the administration of risperdone at a 337 
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prepulse of 74 dB (p < 0.01) and 78 dB (p < 0.05) (Fig 4B, F(7, 108) = 2.293). 338 
 339 
Fig 4. Reversal of sensorimotor gating deficit in the PPI task following the administration of 340 
risperidone in the NAc-TMEM mice (A) Risperidone (0.01 mg/kg i.p.) or saline was administrated 341 
30 min before the task performance. Startle responses was measured at 70, 80, 90, 100, 110, and 120 342 
dB, respectively (background noise: 70 dB), N = 8; values are presented as mean ± S.E.M. No 343 
significant difference between NAc-TMEM and NAc-Mock mice (two-way ANOVA followed by the 344 
Bonferroni’s post hoc tests). (B) Risperidone (0.01 mg/kg i.p.) or saline was administered 30 min 345 
before the task performance. PPI was measured for 74, 78, 82, and 86 dB respectively, of prepulse 346 
intensity (background noise: 70 dB), N = 8; values are presented as mean ± S.E.M. **p < 0.01, *p < 347 
0.05 vs. NAc-TMEM (VEH) (two-way ANOVA followed by the Bonferroni’s post hoc tests). VEH: 348 
saline administration group, RIS: risperidone administration group. 349 
 350 
Overexpression of TMEM168 in the NAc did not change the total 351 
contents of glutamate and GABA, but decreased the basal levels of 352 
accumbal extracellular GABA and high K⁺ -stimulated GABA 353 
release from the NAc 354 
The contents of GABA and glutamate in the NAc were analyzed by HPLC. No difference was 355 
observed between the NAc-TMEM and NAc-Mock mice (Fig 5A, F(1, 40) = 0.5878). The TMEM168 356 
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overexpression inhibited the basal extracellular GABA levels (Fig 5B, p < 0.05, t = 2.281). Moreover, 357 
GABA release following the potassium stimulation was decreased in the NAc-TMEM mice when 358 
compared to the NAc-Mock animals (Fig 5C, p < 0.01, F(6, 60) = 7.683). These results suggest that 359 
TMEM168 baseline overexpression attenuated GABA neurotransmission in the NAc. 360 
 361 
Fig 5. Inhibitory effects of TMEM168 on GABA neurotransmission in the NAc (A) Glutamate 362 
(GLU) and GABA concentrations in the NAc tissue were measured by HPLC. The NAc-Mock mice 363 
and NAc-TMEM mice were sacrificed and then the NAc tissue was extracted immediately, N = 11; 364 
values are presented as mean ± S.E.M. No significant difference between NAc-TMEM and 365 
NAc-Mock mice (two-way ANOVA followed by the Bonferroni’s post hoc tests). (B) Basal levels of 366 
extracellular GABA in the NAc were detected by the in vivo microdialysis task, N = 6; values are 367 
presented as mean ± S.E.M. *p < 0.05 vs. NAc-Mock (Student-t test). (C) Dynamic changes in the 368 
extracellular GABA levels in the NAc after high K⁺-stimulation was analyzed in the NAc by the in 369 
vivo microdialysis task, N = 6; values are given as mean ± S.E.M. **p < 0.01 vs. NAc-Mock. 370 
(ANOVA with repeated measures followed by the Bonferroni’s post hoc test) (D) Basal levels of 371 
extracellular dopamine in the NAc were detected by the in vivo microdialysis task, N = 4; values are 372 
presented as mean ± S.E.M. No significant difference between NAc-TMEM and NAc-Mock mice 373 
(Student-t test). (E) Basal levels of extracellular serotonin in the NAc were detected by the in vivo 374 
microdialysis task, N = 3–4; values are given as mean ± S.E.M. No significant difference between 375 
Fu et al. 
23 
 
NAc-TMEM and NAc-Mock mice (Student-t test). 376 
 377 
Overexpression of TMEM168 did not change the basal amount of 378 
extracellular dopamine and serotonin in the NAc 379 
The basal levels of accumbal extracellular dopamine (Fig 5D, t = 0.5635) and serotonin (Fig 5E, t = 380 
0.09495) in the NAc-Mock and NAc-TMEM mice were analyzed using the in vivo microdialysis 381 
method. No significant between-group difference was observed. 382 
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DISCUSSION 383 
Both sensorimotor gating deficit and increased anxiety are often found in patients with addiction 384 
disorder [4, 28]. Repeated METH administration in rodents is usually used as a model to mimic the 385 
decreased PPI and anxiety in schizophrenia [21, 29, 30]; however, a clear link between METH 386 
addiction and emotional properties or sensorimotor gating function still needs to be assessed. In the 387 
present study, we found that the increased METH related molecule TMEM168 in the nucleus 388 
accumbens, induced anxiety in the elevated plus-maze and light/dark box tasks, and resulted in 389 
sensorimotor gating deficit in the auditory PPI task. These findings suggest that TMEM168 in the NAc 390 
is crucial for the modulation of anxiety and schizophrenia-like behaviors in mice. 391 
GABA is a primary inhibitory neurotransmitter associated with emotion regulation anomalies, 392 
including anxiety and panic disorders [31]. Specifically, the reduced concentration of GABA is 393 
thought to be associated with increased anxiety levels [31]. As the injected AAV-TMEM168 vector can 394 
transduce into local neurons preferentially [32, 33], approximately 99% of the affected neuronal 395 
populations in the NAc of NAc-TMEM mice should be GABA neurons [2, 34]. In vivo microdialysis 396 
analysis revealed that the basal levels of extracellular GABA were reduced in the NAc, and GABA 397 
release was also reduced after K+ stimulation in the NAc-TMEM mice when compared with the 398 
control mice. Furthermore, the pharmacological action of anxiety reducing drug, diazepam, which is 399 
known to facilitate GABAergic transmission by binding GABAA receptors [22], reversed the 400 
TMEM168 overexpression-induced anxiety as measured in both the elevated plus-maze and light/dark 401 
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box tasks. These results suggest that a reduction in GABAergic neurotransmission could be linked to 402 
TMEM168-induced anxious behaviors.  403 
The trigger of anxiety is a complex process in the brain, which is related to the activity in multiple 404 
neural circuits. Briefly, the amygdala, bed nucleus of the stria terminalis, and prefrontal cortex (PFC) 405 
are usually identified as the key regions controlling anxiety. As a central relay structure between the 406 
amygdala, basal ganglia, ventral tegmental area (VTA), and PFC, the NAc seems to play a modulatory 407 
role in the anxious signal transmission from the amygdaloid complex to the latter areas [35]. In the 408 
present study, we found that GABA release was inhibited following a TMEM168 transfection in the 409 
NAc neurons locally, including 95% GABAergic medium spiny neurons (MSN) projecting to other 410 
brain regions [2, 34]. As the direct projected targets of the accumbal MSN, the VTA and pallidum are 411 
demonstrated to be relevant to anxiety symptoms via GABAergic dysfunction [36, 37]. Thus, the 412 
interrupted GABAergic projection from the NAc might underlie the mechanism of the increased 413 
anxiety in the NAc-TMEM mice.  414 
The NAc-TMEM mice also showed reduced PPI when compared with the NAc-Mock mice in the 415 
present auditory startle response test. Increased dopaminergic and serotoninergic neurotransmission in 416 
the brain is presumed to reduce PPI in rodents [38, 39]. Risperidone is an antagonist of dopamine 417 
receptor D2, and serotonin receptor 2A in multiple brain regions [40]. In the present study, risperidone 418 
reversed the sensorimotor gating deficit associated with the overexpression of TMEM168 in the NAc. 419 
This might indicate that the overexpression of TMEM168 in the NAc could mediate sensorimotor 420 
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deficits through an increase of dopaminergic or serotoninergic activity. However, no significant 421 
difference in accumbal extracellular dopamine or serotonin between the NAc-TMEM and NAc-Mock 422 
mice was observed. Numerous animal and human studies have indicated that sensorimotor gating 423 
function is regulated by the cortico-striatal-pallido circuit [24, 41]. Hence, the interruption in the NAc 424 
might not be a solitary part of the integral neural pathways. There is a possibility that the 425 
dopaminergic and serotoninergic functions in other accumbal relevant regions such as the PFC, 426 
striatum, and pallidum are indirectly affected by the GABAergic suppression in the NAc, and their 427 
dysfunctions are subsequently normalized by the administration of risperidone in the NAc-TMEM 428 
mice. Although the neurotransmissions in these accumbal relevant regions of the NAc-TMEM mice 429 
are needed to be analyzed in the next study, the functional roles of accumbal TMEM168 in the 430 
METH-induced schizophrenia-like behaviors were demonstrated firstly in the present experiment. As 431 
TMEM168 is an adaptive molecule responding to METH exposure, the study of the increased 432 
TMEM168 in the NAc might open a branch to elucidate the mechanism of the METH-induced 433 
psychotic complications, of which one characteristic symptom is sensorimotor gating deficit. 434 
The downstream signaling pathways of TMEM168 in influencing GABAergic activity or behavioral 435 
events still remain unclear. Repeated administration of METH does not influence the extracellular 436 
GABA levels in the NAc, but the overexpression of TMEM168 via the AAV vector transfection 437 
inhibits the accumbal GABA release. It is suggested that TMEM168 may play some functional roles in 438 
GABAergic regulation independent on the pharmacological effect of METH. The Crk-like protein 439 
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(CrkL), for example, has been found to interact with TMEM168 in a yeast two-hybrid screening study 440 
[42]. CrkL, collectively with Crk, participates in the reelin signaling cascade downstream of DAB1 441 
[43, 44]. The reduced expression of reelin can weaken the GABAergic neurotransmission in 442 
transgenic mice and also schizophrenia or bipolar patients [45-48]. Thus, it could be suggested that the 443 
activation of the TMEM168-CrkL-reelin pathway might induce behavioral changes in the 444 
NAc-TMEM mice altering the GABAergic neurotransmission. Furthermore, in a previous study, we 445 
found that extracellular osteopontin (OPN) was increased in the NAc-TMEM mice [14]. Activation of 446 
integrin receptors is usually determined as the downstream signaling pathway of the secreted OPN 447 
[49]. Mutations of β1- and β3-containing integrins in mice have been linked to anxiety disorders [50]. 448 
Thus, the TMEM168-OPN-integrin receptor could also be implicated in the mechanisms underpinning 449 
TMEM168-effects on behavior.  450 
In summary, TMEM168 overexpression in the NAc neurons could induce a decrease in the 451 
extracellular GABA levels in the NAc, with effects on both anxiety levels and sensorimotor gating 452 
ability. Future research should further explore the role of TMEM168 in emotional properties or 453 
sensorimotor gating function.  454 
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